Compare Gilead Sciences, Inc. (GILD) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Nutanix Inc — how do they compare? Gilead Sciences, Inc. trades at $151.12 (market cap $182.40B), while Nutanix Inc trades at $74.07 (market cap $19.78B). The key difference: Gilead Sciences, Inc. is far larger — about 9.2× Nutanix Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Nutanix Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Nutanix Inc for 17 Days on average.
| GILD | NTNX | |
|---|---|---|
Market Cap | $182.40B | $19.78B |
Volume | 4,469,821 | 1,717,619 |
Sector | Health | Technology |
52-Week High | $155.80 | $73.42 |
52-Week Low | $116.74 | $34.41 |
Typical Hold Time | 111 Days | 17 Days |
Enterprise Value | $205.46B | $18.94B |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
Nutanix (NTNX) trades at $73.24, down slightly by 0.25% today, but maintains a bullish technical outlook with strong analyst support. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.60 beating expectations of $0.49, and impressive profitability with an 86.8% gross margin. Recent Gartner Magic Quadrant recognitions highlight competitive strength in virtualization and container management platforms, supporting positive market sentiment.
The investment outlook remains positive with a consensus price target of $76.11 representing 4% upside potential. Key opportunities include external storage partnerships and AI growth initiatives, while risks involve high valuation multiples (EV/EBITDA of 46.22) and negative ROE of -395.76%. Institutional ownership trends and 62.5% analyst buy ratings suggest continued Wall Street confidence in the company's execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
